xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT05986214</url>
    </required_header>
    <id_info>
      <org_study_id>CDX 23-001</org_study_id>
      <secondary_id>CDA 21-187</secondary_id>
      <nct_id>NCT05986214</nct_id>
    </id_info>
    <brief_title>Developing an Intervention to Optimize Virtual Care Adoption for COPD Management</brief_title>
    <acronym>VC-OPTIONS</acronym>
    <official_title>Developing an Intervention to Optimize Virtual Care Adoption for COPD Management (CDA 21-187)</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>VA Office of Research and Development</agency>
        <agency_class>U.S. Fed</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>VA Office of Research and Development</source>
    <oversight_info>
      <has_dmc>No</has_dmc>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
      <is_us_export>No</is_us_export>
    </oversight_info>
    <brief_summary>
      <textblock>
        VA is a leader in virtual care (VC), including the patient portal, mobile apps, and&#xD;
        telehealth programs. VC has great utility for managing chronic conditions like chronic&#xD;
        obstructive pulmonary disease (COPD). However, adoption of many VC services has been slow.&#xD;
        Lack of awareness about these services is one of the most prominent patient- and healthcare&#xD;
        team-facing barriers to adopting VC. This study will develop, refine, and pilot a&#xD;
        stakeholder-informed multicomponent implementation strategy to support adoption of VC,&#xD;
        referred to as VC-OPTIONS (Virtual Care for Chronic Obstructive Pulmonary Disease Adoption&#xD;
        Support). This feasibility trial will pilot the VC-OPTIONS implementation strategy to assess&#xD;
        feasibility and acceptability and gather preliminary effectiveness data to inform a larger&#xD;
        hybrid effectiveness-implementation trial. The core component of VC-OPTIONS will be the&#xD;
        provision of information via VA's Annie texting program to empower patients with knowledge&#xD;
        about the array of VC services and how they can be used to support COPD management. It is&#xD;
        hypothesized that this strategy will be acceptable and feasible. This work will improve&#xD;
        patient and team awareness of and communication about VC services, and support patient access&#xD;
        to VC services for COPD management.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        VA is a leader in virtual care (VC), including the patient portal, mobile apps, and&#xD;
        telehealth programs. VC has great utility for managing chronic conditions like chronic&#xD;
        obstructive pulmonary disease (COPD). However, adoption of many VC services has been slow.&#xD;
        Lack of awareness about these services is one of the most prominent patient- and healthcare&#xD;
        team-facing barriers to adopting VC. This study will develop, refine, and pilot a&#xD;
        stakeholder-informed multicomponent implementation strategy to support adoption of VC,&#xD;
        referred to as VC-OPTIONS (Virtual Care for Chronic Obstructive Pulmonary Disease Adoption&#xD;
        Support). This single-arm pilot will assess the feasibility and acceptability of VC-OPTIONS,&#xD;
        as well as engagement and preliminary effectiveness specific to VC adoption, such as change&#xD;
        in patient awareness of VC services. The investigators hypothesize that developing&#xD;
        educational content about VC that can be delivered via text messaging will be an effective&#xD;
        way to empower Veterans with knowledge and support them in their decision to adopt VC if they&#xD;
        are interested.&#xD;
  &#xD;
        Setting and design.&#xD;
  &#xD;
        This feasibility pilot will be conducted at the VA Bedford and/or Boston Healthcare Systems.&#xD;
        This pilot study will use quantitative data to assess patient and team perceptions of&#xD;
        feasibility and acceptability, and preliminary effectiveness of the intervention. VC-OPTIONS&#xD;
        will include patient- and team-facing strategies. The core component will be the delivery of&#xD;
        educational content about VC for COPD via Annie text messaging. Other patient- and healthcare&#xD;
        team-facing strategies will be refined in prior, preparatory aims.&#xD;
  &#xD;
        Patient level. 40 eligible and interested Veterans will be assigned to the core&#xD;
        patient-facing implementation strategy, the Annie texting protocol. Preparatory work will&#xD;
        shape final length of protocol, content, and frequency of messages. The texting protocol as&#xD;
        currently envisioned will span 12 weeks (1 module [Appendix 5] with up to 5 messages per&#xD;
        week, and 2 messages every 4 weeks that ask about behavioral intention). Participants will&#xD;
        receive compensation for initial baseline assessments and additional compensation after&#xD;
        completion of the follow-up assessments.&#xD;
  &#xD;
        Team-level. Pre-implementation meetings with local clinical team stakeholders (e.g.,&#xD;
        leadership, clinical team members, local telehealth/connected care coordinators) will be held&#xD;
        to discuss site-level needs and contextual factors. Potential team-facing strategy&#xD;
        components, developed during preparatory aims, will be presented and discussed to reach&#xD;
        consensus and finalize the team-facing strategy components that are tailored to the&#xD;
        site-level needs and resources.&#xD;
  &#xD;
        Data collection. Patient-level. Recruitment procedures will be evaluated to inform a&#xD;
        subsequent larger trial by examining how many potential participants agreed to participate in&#xD;
        the intervention (feasibility and acceptability), and documenting reasons Veterans declined&#xD;
        to participate. Participants will complete a baseline survey in person or over the phone to&#xD;
        gather participant characteristics, VC awareness, current use of VC, and intent to use VC.&#xD;
        Using Annie's two-way texting feature and dashboard, objective data will be collected on&#xD;
        participant engagement during the protocol (i.e., how frequently participants respond to the&#xD;
        texts, which patients received which modules, and completion rates). Engagement will also be&#xD;
        assessed via survey at the post-evaluation. After completion of the texting protocol and&#xD;
        clinical visit, data will be obtained via survey on the feasibility and acceptability of the&#xD;
        core implementation component using the Feasibility of Intervention, Acceptability of&#xD;
        Intervention, and Intervention Appropriateness measures. Preliminary effectiveness data will&#xD;
        be gathered via surveys and clinical chart review on participants' awareness of VC, intention&#xD;
        to adopt one or more VC options, intention to discuss VC with their clinical team, occurrence&#xD;
        of patient-team communication about VC, and impact on COPD management.&#xD;
  &#xD;
        Team-level. Clinical team perceptions of feasibility and acceptability will be measured&#xD;
        quantitatively, such as through a brief survey to clinical team members who were exposed to&#xD;
        the implementation components (e.g., those who attended the educational meetings, those who&#xD;
        participated in clinical visits with participants who were enrolled in the texting protocol).&#xD;
        Engagement will be measured by examining attendance of educational meetings. Preliminary&#xD;
        effectiveness outcomes data will also be collected, including survey and chart-review to&#xD;
        identify occurrence of conversations with patients about VC services (anticipated primary&#xD;
        outcome of future IIR) and referrals to the Virtual Health Resource Centers or telehealth&#xD;
        services and surveys to evaluate awareness of VC services before/after strategy deployment.&#xD;
  &#xD;
        Data analysis. Summary statistics will be used to examine measurements and assess for&#xD;
        perceptions of feasibility, acceptability, and preliminary effectiveness of the&#xD;
        implementation strategy. The strategy components (the texting protocol, recruitment, and data&#xD;
        collection procedures) will further be refined based on what is learned. Inferential analyses&#xD;
        (paired t-tests or Wilcoxon signed rank tests) will be used to estimate effect sizes of&#xD;
        changes between pre/post timepoints within individual participant. This feasibility pilot is&#xD;
        not intended or powered to detect statistically significant changes in outcomes.&#xD;
        Additionally, this pilot with no prospective control arm cannot definitively ascertain&#xD;
        whether VC-OPTIONS causes leads to changes in effectiveness. These preliminary analyses seek&#xD;
        to inform the design and generate effect size estimates.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Not yet recruiting</overall_status>
    <start_date type="Anticipated">March 1, 2026</start_date>
    <completion_date type="Anticipated">August 31, 2028</completion_date>
    <primary_completion_date type="Anticipated">September 1, 2027</primary_completion_date>
    <phase>N/A</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>N/A</allocation>
      <intervention_model>Single Group Assignment</intervention_model>
      <intervention_model_description>All patient participants will all be assigned to the VC-OPTIONS implementation strategy</intervention_model_description>
      <primary_purpose>Health Services Research</primary_purpose>
      <masking>None (Open Label)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>Feasibility</measure>
      <time_frame>12 Weeks</time_frame>
      <description>The feasibility of the core implementation component will be assessed with the Feasibility of Intervention Measure (FIM). This is a publicly available, psychometrically sound scale designed to be used in pilot studies as an indicator of implementation success. Participants will be asked to indicate the extent to which they agree with the following statements on a scale from 1 (completely disagree) to 5 (completely agree): I can see other Veterans receiving these messages; I was able to respond to the text messages; texting with Annie was easy; the amount of messages I received from Annie was just right.</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Acceptability</measure>
      <time_frame>12 Weeks</time_frame>
      <description>The acceptability of the core implementation component will be assessed with the Acceptability of Intervention Measure (AIM). This is a publicly available, psychometrically sound scale designed to be used in pilot studies as an indicator of implementation success. Participants will be asked to indicate the extent to which they agree with the following statements on a scale from 1 (completely disagree) to 5 (completely agree): I approved of the text messages I received; the text messages I received were appealing to me; I liked receiving and responding to the text messages I received; I welcomed the text messages I received.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Appropriateness</measure>
      <time_frame>12 Weeks</time_frame>
      <description>The appropriateness of the core implementation component will be assessed with the Intervention Appropriateness Measure (IAM). This is a publicly available, psychometrically sound scale designed to be used in pilot studies as an indicator of implementation success. Participants will be asked to indicate the extent to which they agree with the following statements on a scale from 1 (completely disagree) to 5 (completely agree): the text messages were fitting; the text messages were suitable, the text messages were applicable to me; the text messages were a good match with my COPD management needs.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Awareness of Virtual Care</measure>
      <time_frame>12 Weeks</time_frame>
      <description>Change between baseline and 12 weeks in awareness of Virtual Care services will be assessed via survey, pre and post intervention, through the following question: which of the following VA services are you aware of?</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Intention to Adopt Virtual Care</measure>
      <time_frame>Baseline and 12 weeks</time_frame>
      <description>Change between baseline and 12 weeks in awareness of Virtual Care services will be assessed via survey through the following question: which of the following VA services are you interested in trying out?</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Intent to Communicate about Virtual Care</measure>
      <time_frame>Baseline and 12 weeks</time_frame>
      <description>Change between baseline and 12 weeks will assess intent to communicate about Virtual Care from baseline to post-intervention (12 weeks) through the following questions: how interested are you in discussing these different services with your healthcare team; and how prepared do you feel to discuss these different services with your healthcare team? Participants will indicate on a 4-point scale from &quot;not very&quot; to &quot;very.&quot;</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Impact of COPD Management</measure>
      <time_frame>12 weeks</time_frame>
      <description>Participants will be asked to describe via free text any impacts participation in this study had on their COPD management.</description>
    </secondary_outcome>
    <number_of_arms>1</number_of_arms>
    <enrollment type="Anticipated">40</enrollment>
    <condition>Chronic Obstructive Pulmonary Disease</condition>
    <arm_group>
      <arm_group_label>VC-OPTIONS</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Participants will be enrolled in the Annie texting VC-OPTIONS protocol</description>
    </arm_group>
    <intervention>
      <intervention_type>Other</intervention_type>
      <intervention_name>VC-OPTIONS</intervention_name>
      <description>Participants will be enrolled in the Annie texting VC-OPTIONS protocol</description>
      <arm_group_label>VC-OPTIONS</arm_group_label>
      <other_name>Texting Intervention</other_name>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            -  VHA user&#xD;
  &#xD;
            -  US Veteran&#xD;
  &#xD;
            -  COPD diagnosis&#xD;
  &#xD;
            -  the ability to speak and understand English&#xD;
  &#xD;
            -  own a text-enabled phone&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            -  Prior participation in preparatory research for the development of the intervention&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>40 Years</minimum_age>
      <maximum_age>N/A</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Stephanie Robinson, PhD</last_name>
      <role>Principal Investigator</role>
      <affiliation>VA Bedford HealthCare System, Bedford, MA</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Stephanie Robinson, PhD</last_name>
      <phone>(781) 687-4766</phone>
      <email>stephanie.robinson5@va.gov</email>
    </overall_contact>
    <overall_contact_backup>
      <last_name>Saige M Calkins, MA BA</last_name>
      <phone>(781) 687-4414</phone>
      <phone_ext>4414</phone_ext>
      <email>saige.calkins@va.gov</email>
    </overall_contact_backup>
    <location>
      <facility>
        <name>VA Bedford HealthCare System, Bedford, MA</name>
        <address>
          <city>Bedford</city>
          <state>Massachusetts</state>
          <zip>01730-1114</zip>
          <country>United States</country>
        </address>
      </facility>
      <contact>
        <last_name>Stephanie Robinson, PhD</last_name>
        <phone>781-687-4766</phone>
        <email>stephanie.robinson5@va.gov</email>
      </contact>
      <contact_backup>
        <last_name>Saige M Calkins, MA BA</last_name>
        <phone>(781) 687-4414</phone>
        <phone_ext>4414</phone_ext>
        <email>saige.calkins@va.gov</email>
      </contact_backup>
      <investigator>
        <last_name>Stephanie Robinson, PhD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA</name>
        <address>
          <city>Boston</city>
          <state>Massachusetts</state>
          <zip>02130-4817</zip>
          <country>United States</country>
        </address>
      </facility>
      <contact>
        <last_name>Renda Wiener, MD</last_name>
        <email>renda.wiener@va.gov</email>
      </contact>
      <contact_backup>
        <last_name>Marilyn Moy, MD</last_name>
        <email>Marilyn.Moy@va.gov</email>
      </contact_backup>
    </location>
    <location_countries>
      <country>United States</country>
    </location_countries>
    <verification_date>July 2023</verification_date>
    <study_first_submitted>July 31, 2023</study_first_submitted>
    <study_first_submitted_qc>August 9, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 14, 2023</study_first_posted>
    <last_update_submitted>August 9, 2023</last_update_submitted>
    <last_update_submitted_qc>August 9, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 14, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <keyword>Pulmonary Disease, Chronic Obstructive</keyword>
    <keyword>Telemedicine</keyword>
    <keyword>Text Messaging</keyword>
    <keyword>Implementation Science</keyword>
    <keyword>Community-Based Participatory Research</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Lung Diseases</mesh_term>
      <mesh_term>Lung Diseases, Obstructive</mesh_term>
      <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    </condition_browse>
    <patient_data>
      <sharing_ipd>No</sharing_ipd>
      <ipd_description>There is not a plan to make IPD available. Data will be used by the research team only to inform manuscripts and future grant submissions.</ipd_description>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT05986214
  org study id: CDX 23-001
  secondary id: CDA 21-187
  nct id: NCT05986214
  lead sponsor: 
  has dmc: No
  is fda regulated drug: No
  is fda regulated device: No
  is us export: No
  VA is a leader in virtual care (VC), including the patient portal, mobile apps, and
        telehealth programs. VC has great utility for managing chronic conditions like chronic
        obstructive pulmonary disease (COPD). However, adoption of many VC services has been slow.
        Lack of awareness about these services is one of the most prominent patient- and healthcare
        team-facing barriers to adopting VC. This study will develop, refine, and pilot a
        stakeholder-informed multicomponent implementation strategy to support adoption of VC,
        referred to as VC-OPTIONS (Virtual Care for Chronic Obstructive Pulmonary Disease Adoption
        Support). This feasibility trial will pilot the VC-OPTIONS implementation strategy to assess
        feasibility and acceptability and gather preliminary effectiveness data to inform a larger
        hybrid effectiveness-implementation trial. The core component of VC-OPTIONS will be the
        provision of information via VA's Annie texting program to empower patients with knowledge
        about the array of VC services and how they can be used to support COPD management. It is
        hypothesized that this strategy will be acceptable and feasible. This work will improve
        patient and team awareness of and communication about VC services, and support patient access
        to VC services for COPD management.
  VA is a leader in virtual care (VC), including the patient portal, mobile apps, and
        telehealth programs. VC has great utility for managing chronic conditions like chronic
        obstructive pulmonary disease (COPD). However, adoption of many VC services has been slow.
        Lack of awareness about these services is one of the most prominent patient- and healthcare
        team-facing barriers to adopting VC. This study will develop, refine, and pilot a
        stakeholder-informed multicomponent implementation strategy to support adoption of VC,
        referred to as VC-OPTIONS (Virtual Care for Chronic Obstructive Pulmonary Disease Adoption
        Support). This single-arm pilot will assess the feasibility and acceptability of VC-OPTIONS,
        as well as engagement and preliminary effectiveness specific to VC adoption, such as change
        in patient awareness of VC services. The investigators hypothesize that developing
        educational content about VC that can be delivered via text messaging will be an effective
        way to empower Veterans with knowledge and support them in their decision to adopt VC if they
        are interested.
  
        Setting and design.
  
        This feasibility pilot will be conducted at the VA Bedford and/or Boston Healthcare Systems.
        This pilot study will use quantitative data to assess patient and team perceptions of
        feasibility and acceptability, and preliminary effectiveness of the intervention. VC-OPTIONS
        will include patient- and team-facing strategies. The core component will be the delivery of
        educational content about VC for COPD via Annie text messaging. Other patient- and healthcare
        team-facing strategies will be refined in prior, preparatory aims.
  
        Patient level. 40 eligible and interested Veterans will be assigned to the core
        patient-facing implementation strategy, the Annie texting protocol. Preparatory work will
        shape final length of protocol, content, and frequency of messages. The texting protocol as
        currently envisioned will span 12 weeks (1 module [Appendix 5] with up to 5 messages per
        week, and 2 messages every 4 weeks that ask about behavioral intention). Participants will
        receive compensation for initial baseline assessments and additional compensation after
        completion of the follow-up assessments.
  
        Team-level. Pre-implementation meetings with local clinical team stakeholders (e.g.,
        leadership, clinical team members, local telehealth/connected care coordinators) will be held
        to discuss site-level needs and contextual factors. Potential team-facing strategy
        components, developed during preparatory aims, will be presented and discussed to reach
        consensus and finalize the team-facing strategy components that are tailored to the
        site-level needs and resources.
  
        Data collection. Patient-level. Recruitment procedures will be evaluated to inform a
        subsequent larger trial by examining how many potential participants agreed to participate in
        the intervention (feasibility and acceptability), and documenting reasons Veterans declined
        to participate. Participants will complete a baseline survey in person or over the phone to
        gather participant characteristics, VC awareness, current use of VC, and intent to use VC.
        Using Annie's two-way texting feature and dashboard, objective data will be collected on
        participant engagement during the protocol (i.e., how frequently participants respond to the
        texts, which patients received which modules, and completion rates). Engagement will also be
        assessed via survey at the post-evaluation. After completion of the texting protocol and
        clinical visit, data will be obtained via survey on the feasibility and acceptability of the
        core implementation component using the Feasibility of Intervention, Acceptability of
        Intervention, and Intervention Appropriateness measures. Preliminary effectiveness data will
        be gathered via surveys and clinical chart review on participants' awareness of VC, intention
        to adopt one or more VC options, intention to discuss VC with their clinical team, occurrence
        of patient-team communication about VC, and impact on COPD management.
  
        Team-level. Clinical team perceptions of feasibility and acceptability will be measured
        quantitatively, such as through a brief survey to clinical team members who were exposed to
        the implementation components (e.g., those who attended the educational meetings, those who
        participated in clinical visits with participants who were enrolled in the texting protocol).
        Engagement will be measured by examining attendance of educational meetings. Preliminary
        effectiveness outcomes data will also be collected, including survey and chart-review to
        identify occurrence of conversations with patients about VC services (anticipated primary
        outcome of future IIR) and referrals to the Virtual Health Resource Centers or telehealth
        services and surveys to evaluate awareness of VC services before/after strategy deployment.
  
        Data analysis. Summary statistics will be used to examine measurements and assess for
        perceptions of feasibility, acceptability, and preliminary effectiveness of the
        implementation strategy. The strategy components (the texting protocol, recruitment, and data
        collection procedures) will further be refined based on what is learned. Inferential analyses
        (paired t-tests or Wilcoxon signed rank tests) will be used to estimate effect sizes of
        changes between pre/post timepoints within individual participant. This feasibility pilot is
        not intended or powered to detect statistically significant changes in outcomes.
        Additionally, this pilot with no prospective control arm cannot definitively ascertain
        whether VC-OPTIONS causes leads to changes in effectiveness. These preliminary analyses seek
        to inform the design and generate effect size estimates.
  allocation: N/A
  intervention model: Single Group Assignment
  intervention model description: All patient participants will all be assigned to the VC-OPTIONS implementation strategy
  primary purpose: Health Services Research
  masking: None (Open Label)
  measure: Feasibility
  time frame: 12 Weeks
  description: The feasibility of the core implementation component will be assessed with the Feasibility of Intervention Measure (FIM). This is a publicly available, psychometrically sound scale designed to be used in pilot studies as an indicator of implementation success. Participants will be asked to indicate the extent to which they agree with the following statements on a scale from 1 (completely disagree) to 5 (completely agree): I can see other Veterans receiving these messages; I was able to respond to the text messages; texting with Annie was easy; the amount of messages I received from Annie was just right.
  measure: Acceptability
  time frame: 12 Weeks
  description: The acceptability of the core implementation component will be assessed with the Acceptability of Intervention Measure (AIM). This is a publicly available, psychometrically sound scale designed to be used in pilot studies as an indicator of implementation success. Participants will be asked to indicate the extent to which they agree with the following statements on a scale from 1 (completely disagree) to 5 (completely agree): I approved of the text messages I received; the text messages I received were appealing to me; I liked receiving and responding to the text messages I received; I welcomed the text messages I received.
  measure: Appropriateness
  time frame: 12 Weeks
  description: The appropriateness of the core implementation component will be assessed with the Intervention Appropriateness Measure (IAM). This is a publicly available, psychometrically sound scale designed to be used in pilot studies as an indicator of implementation success. Participants will be asked to indicate the extent to which they agree with the following statements on a scale from 1 (completely disagree) to 5 (completely agree): the text messages were fitting; the text messages were suitable, the text messages were applicable to me; the text messages were a good match with my COPD management needs.
  measure: Awareness of Virtual Care
  time frame: 12 Weeks
  description: Change between baseline and 12 weeks in awareness of Virtual Care services will be assessed via survey, pre and post intervention, through the following question: which of the following VA services are you aware of?
  measure: Intention to Adopt Virtual Care
  time frame: Baseline and 12 weeks
  description: Change between baseline and 12 weeks in awareness of Virtual Care services will be assessed via survey through the following question: which of the following VA services are you interested in trying out?
  measure: Intent to Communicate about Virtual Care
  time frame: Baseline and 12 weeks
  description: Change between baseline and 12 weeks will assess intent to communicate about Virtual Care from baseline to post-intervention (12 weeks) through the following questions: how interested are you in discussing these different services with your healthcare team; and how prepared do you feel to discuss these different services with your healthcare team? Participants will indicate on a 4-point scale from "not very" to "very."
  measure: Impact of COPD Management
  time frame: 12 weeks
  description: Participants will be asked to describe via free text any impacts participation in this study had on their COPD management.
  arm group label: VC-OPTIONS
  arm group type: Experimental
  description: Participants will be enrolled in the Annie texting VC-OPTIONS protocol
  intervention type: Other
  intervention name: VC-OPTIONS
  description: Participants will be enrolled in the Annie texting VC-OPTIONS protocol
  arm group label: VC-OPTIONS
  other name: Texting Intervention
  criteria: 
  gender: All
  minimum age: 40 Years
  maximum age: N/A
  healthy volunteers: No
  last name: Stephanie Robinson, PhD
  role: Principal Investigator
  affiliation: VA Bedford HealthCare System, Bedford, MA
  last name: Stephanie Robinson, PhD
  phone: (781) 687-4766
  email: stephanie.robinson5@va.gov
  last name: Saige M Calkins, MA BA
  phone: (781) 687-4414
  phone ext: 4414
  email: saige.calkins@va.gov
  facility: 
  contact: 
  contact backup: 
  investigator: 
  facility: 
  contact: 
  contact backup: 
  country: United States
  responsible party type: Sponsor
  mesh term: Lung Diseases
  mesh term: Lung Diseases, Obstructive
  mesh term: Pulmonary Disease, Chronic Obstructive
  sharing ipd: No
  ipd description: There is not a plan to make IPD available. Data will be used by the research team only to inform manuscripts and future grant submissions.